Personalized mRNA melanoma vaccine cuts recurrence risk 42% in trial

A personalized mRNA cancer vaccine reduced melanoma recurrence risk by 42% versus standard care in a clinical trial. The result is promising but early-stage; regulatory approval and broader efficacy remain uncertain. This could shift oncology treatment paradigms if confirmed.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works